• Office: 208 Pavilion
  • Phone: 412-624-4683
  • Fax: (412) 624-1850
  • Email: nolin@pitt.edu
orcidpubmedLinkedIn

Dr. Nolin is an Associate Professor with tenure in the School of Pharmacy, Department of Pharmacy and Therapeutics, and holds a secondary appointment in the Department of Medicine Renal Electrolyte Division. He received his BS in Pharmacy from the University of Connecticut, and then completed a residency and MS in Hospital Pharmacy from the University of North Carolina at Chapel Hill. After working for several years as a clinical pharmacy specialist in nephrology and transplantation at Maine Medical Center (MMC) in Portland, Maine, Dr. Nolin matriculated to the University of Pittsburgh where he received a PharmD and a PhD in Clinical Pharmaceutical Sciences with concentration in drug metabolism/pharmacokinetics.

Evaluation of the functional expression of drug metabolizing enzymes and transporters in humans, and clinical PK/PD in patients with kidney disease.

SELECTED PEER REVIEWED PUBLICATIONS (2012-2014)

1. Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. J Clin Pharmacol 2012;52(Suppl 1):10S-22S. PMID: 22232747.

2. Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307(23):2495-2496. PMID: 22797448.

3. Peng ZY, Zhou F, Wang HZ, Wen XY, Nolin TD, Bishop JV, Kellum JA. The anti-oxidant effects are not the main mechanism for glutamine's protective effects on acute kidney injury in mice. Eur J Pharmacol 2013;705(1-3):11-19. PMID: 23454558.

4. Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: The PARADOX study. J Am Coll Cardiol 2013;62(6):505-512. PMID: 23602770.

5. Bliden KP, Baker BA, Nolin TD, Jeong YH, Bailey WL, Tantry US, Gurbel PA. Thienopyridine efficacy and cigarette smoking status. Am Heart J 2013;165(5):693-703. PMID: 23622905.

6. Singh T, Maw TT, Henry BL, Unruh ML, Hallows KR, Nolin TD*. Use of extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: A single center experience. Clin J Am Soc Nephrol 2013;8(9):1533-1539. PMID: 23704302.

7. Joy MS, Frye RF, Nolin TD, Roberts BV, La MK, Wang J, Brouwer KLR, Dooley MA, Falk RJ. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy 2014;34(2):114-122. PMID: 24038489.

8. Alshogran OY, Ocque AJ, Zhao J, Day BW, Leblond FA, Pichette V, Nolin TD*. Determination of warfarin alcohols by ultra-high performance liquid chromatography-tandem mass spectrometry: Application to in vitro enzyme kinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2014;944:63-68. PMID: 24291722.

9. Ghannoum M, Nolin TD*. What is the role of renal replacement therapy in the setting of dabigatran toxicity? Semin Dial 2014;27(3):223-226. PMID: 24620942.

10. Ghannoum M, Bouchard J, Nolin TD, Ouellet G, Roberts DM. Hemoperfusion for the treatment of poisoning: Technology, determinants of poison clearance, and application in clinical practice. Semin Dial 2014;27(4):350-361. PMID: 24823936.

11. Tortorici MA, Nolin TD*. Kidney function assessment and its role in drug development, review and utilization. Expert Rev Clin Pharmacol 2014;7(4):523-532. PMID: 24875237.

12. Goldstein SL, Nolin TD*. Lack of drug dosing guidelines for critically ill patients receiving continuous renal replacement therapy. Clin Pharmacol Ther 2014;96(2):159-161. PMID: 24810205.

13. Stubbs JR, Zhang S, Friedman PA, Nolin TD. Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with chronic kidney disease. Clin J Am Soc Nephrol 2014;9(11):1965-73. PMID: 25183657.

14. Nolin TD*, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Breyer MD, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL. Pharmacokinetic assessment in patients receiving continuous RRT: Perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol 2015;10(1):159-64. PMID: 25189923.

15. Alshogran OY, Naud J, Ocque AJ, Leblond F, Pichette V, Nolin TD*. Effect of experimental kidney disease on the functional expression of hepatic reductases. Drug Metab Dispos 2015;43(1):100-6. PMID: 25332430.

16. Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis 2014 Nov 21 Epub. PMID: 25453994.

17. Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: A prospective cohort study. Am J Kidney Dis 2014 Nov 25 Epub. PMID: 25468385.

18. Jang SM, Cardone KE, Nolin TD, Mason D, Grabe DW. Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system. BMC Nephrol 2014;15(1):204. PMID: 25526750.

19. Tortorici MA, Cutler D, Hazra A, Nolin TD, Rowland-Yeo K, Venkatakrishnan K. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease. J Clin Pharmacol 2014 Dec 11 Epub. PMID: 25501531.

EXTRIP Workgroup Recommendations:

20. Lavergne V, Nolin TD, Hoffman RS, Roberts D, Gosselin S, Goldfarb DS, Kielstein JT, Mactier R, MacLaren R, Mowry JB, Bunchman TE, Juurlink D, Megarbane B, Anseeuw K, Winchester JF, Dargan P, Liu K, Hoegberg LC, Li Y, Calello DP, Burdmann EA, Yates C, Laliberté M, Decker BS, Mello-da-silva CA, Lavonas E, Ghannoum M. The EXTRIP (EXtracorporeal TReatments In Poisoning) Workgroup: Guideline Methodology. Clin Toxicol (Phila) 2012;50(5):403-13. PMID: 22578059.

21. Ghannoum M, Nolin TD, Goldfarb DS, Roberts D, Mactier R, Mowry JB, Dargan PI, MacLaren R, Hoegberg LC, Laliberté M, Calello D, Kielstein JT, Anseeuw K, Winchester JF, Burdmann EA, Bunchman TE, Li Y, Juurlink D, Lavergne V, Megarbane B, Gosselin S, Liu KD, Hoffman R. Extracorporeal treatment for thallium poisoning: Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2012;7(10):1682-90. PMID: 22837270.

22. Yates C, Galvao T, Sowinski KM, Mardini K, Botnaru T, Gosselin S, Hoffman RS, Nolin TD, Lavergne V, Ghannoum M. Extracorporeal treatment for tricyclic antidepressant poisoning: Recommendations from the EXTRIP Workgroup. Semin Dial 2014;27(4):381-389. PMID: 24712820.

23. Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, Kanji S, Mowry JB, Calello DP, Hoffman RS, Gosselin S, Nolin TD, Goldfarb DS, Burdmann EA, Dargan PI, Decker BS, Hoegberg LC, Maclaren R, Megarbane B, Sowinski KM, Yates C, Mactier R, Wiegand T, Simera I, Ghannoum M. Guidelines for reporting case studies on extracorporeal treatments in poisonings: Methodology. Semin Dial 2014;27(4):407-414. PMID: 24890576.

24. Mactier R, Laliberti´ M, Mardini J, Ghannoum M, Lavergne V, Gosselin S, Hoffman R, Nolin TD*. Extracorporeal treatment for barbiturate poisoning: Recommendations from the EXTRIP workgroup. Am J Kidney Dis 2014;64(3):347-358. PMID: 24998037.

25. Gosselin S, Juurlink D, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, Hoffman RS. Extracorporeal treatment for acetaminophen poisoning: Recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila) 2014;52(8):856-867. PMID: 25133498.

26. Roberts DM, Yates C, Megarbane B, Winchester JF, Maclaren R, Gosselin S, Nolin TD, Levergne V, Hoffman RS, Ghannoum M. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: A systematic review and consensus statement. Crit Care Med 2014 Dec 9 Epub. PMID: 25493973.

27. Ghannoum M, Yates C, Galvao T, Sowinski KM, Vo TH, Coogan A, Gosselin S, Lavergne V, Nolin TD, Hoffman RS. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila) 2014;52(10):993-1004. PMID: 25355482.

Invited Editorials and Commentaries

28. Pfister M, Nolin TD, Arya V. Optimizing drug development and use in patients with kidney disease: Opportunities, innovations and challenges. J Clin Pharmacol 2012;52(Suppl 1):4S-6S. PMID: 22232753.

29. Richardson MM, Nolin TD. A decade after the KDOQI CKD guidelines – Impact on medication safety. Am J Kidney Dis 2012;60(5):713-5. PMID: 23067638.

30. Hudson JQ, Nolin TD*. Estimated GFR and cystatin C for drug dosing: Moving beyond proof of concept to clinical translation? Am J Kidney Dis 2014 Dec 23 Epub. PMID: 25542411.

* Denotes corresponding author

SELECTED PRESENTATIONS (2012-2014)

1. “Unraveling the Effect of Kidney Disease on Nonrenal Drug Clearance.” University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research/Center for Pharmacogenomics Seminar Series, Gainesville, FL, February 24, 2012.

2. “Unraveling the Effects of Kidney Disease on Drug Disposition and Response: The Warfarin Conundrum.” University of Alabama at Birmingham, School of Medicine, Department of Medicine, Division of Nephrology, Nephrology Research and Training Center Noon Conference, Birmingham, AL, March 19, 2012.

3. “Approach for Drug Dosage Adjustments in an Era of Standardized Creatinine, Equation Overload, and Real Patients.” Presented at the National Kidney Foundation 2012 Spring Clinical Meeting, Washington, D.C., May 11, 2012.

4. “Experimental Kidney Failure Leads to Increased Exposure to Warfarin Metabolites.” Presented at Kidney Week 2012, the American Society of Nephrology Annual Meeting, San Diego, CA, November 3, 2012.

5. “Practical Guidelines for Drug Dosing in Patients with Renal Disease/Geriatrics.” Presented at the National Kidney Foundation 2013 Spring Clinical Meeting, Orlando, FL, April 2, 2013.

6. “Top Ten Medication Pitfalls to Avoid.” Presented at the National Kidney Foundation 2013 Spring Clinical Meeting, Orlando, FL, April 2, 2013.

7. “Toxicokinetic Factors that are Important in Determining the Effectiveness of Extracorporeal Elimination Techniques.” Presented at the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) XXXIII International Congress, Copenhagen, Denmark, May 28, 2013.

8. “KHI’s Pilot Projects-Lessons Learned: Pharmacokinetics in Patients Receiving CRRT.” Presented at the Kidney Health Initiative Second Annual Stakeholder’s Meeting, Bethesda, MD, June 12, 2014.

9. “Study Design Considerations: In Vivo Studies in Humans on CRRT.” Presented at the Kidney Health Initiative Open Workshop to present recommendations from the KHI Project titled ‘Standardized Pharmacokinetic Assessment in Patients Receiving Continuous Renal Replacement Therapy (CRRT)’. Held jointly by the American Society of Nephrology and the U.S. FDA in conjunction with the American Society of Nephrology Annual Meeting, Kidney Week 2014, Philadelphia, PA, November 11, 2014.

10. “DAM! It’s not all about Excretion (E); Distribution (D), Absorption (A), and Metabolism/Transport (M) Can also Change in Kidney Diseases.” Presented at the American Society of Nephrology Annual Meeting, Kidney Week 2014, Philadelphia, PA, November 12, 2014.